Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more
Market Cap & Net Worth: Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc (NASDAQ:TBPH) has a market capitalization of $705.36 Million ($705.36 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12583 globally and #5380 in its home market, demonstrating a -0.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theravance Biopharma Inc's stock price $13.92 by its total outstanding shares 50672431 (50.67 Million).
Theravance Biopharma Inc Market Cap History: 2015 to 2026
Theravance Biopharma Inc's market capitalization history from 2015 to 2026. Data shows growth from $830.52 Million to $705.36 Million (0.00% CAGR).
Index Memberships
Theravance Biopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #342 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1240 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #192 of 263 |
Weight: Theravance Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Theravance Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theravance Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.41x
Theravance Biopharma Inc's market cap is 7.41 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $830.52 Million | $42.13 Million | -$182.22 Million | 19.72x | N/A |
| 2016 | $1.62 Billion | $48.65 Million | -$190.67 Million | 33.21x | N/A |
| 2017 | $1.41 Billion | $15.39 Million | -$285.40 Million | 91.85x | N/A |
| 2018 | $1.30 Billion | $60.37 Million | -$215.52 Million | 21.48x | N/A |
| 2019 | $1.31 Billion | $73.41 Million | -$236.46 Million | 17.87x | N/A |
| 2020 | $900.45 Million | $71.86 Million | -$278.02 Million | 12.53x | N/A |
| 2021 | $559.93 Million | $55.31 Million | -$199.43 Million | 10.12x | N/A |
| 2022 | $568.54 Million | $51.35 Million | $872.13 Million | 11.07x | 0.65x |
| 2023 | $569.56 Million | $57.42 Million | -$55.19 Million | 9.92x | N/A |
| 2024 | $476.83 Million | $64.38 Million | -$56.42 Million | 7.41x | N/A |
Competitor Companies of TBPH by Market Capitalization
Companies near Theravance Biopharma Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Theravance Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Theravance Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Theravance Biopharma Inc's market cap moved from $830.52 Million to $ 705.36 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $705.36 Million | -25.60% |
| 2025 | $948.08 Million | +98.83% |
| 2024 | $476.83 Million | -16.28% |
| 2023 | $569.56 Million | +0.18% |
| 2022 | $568.54 Million | +1.54% |
| 2021 | $559.93 Million | -37.82% |
| 2020 | $900.45 Million | -31.36% |
| 2019 | $1.31 Billion | +1.17% |
| 2018 | $1.30 Billion | -8.25% |
| 2017 | $1.41 Billion | -12.52% |
| 2016 | $1.62 Billion | +94.51% |
| 2015 | $830.52 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Theravance Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $705.36 Million USD |
| MoneyControl | $705.36 Million USD |
| MarketWatch | $705.36 Million USD |
| marketcap.company | $705.36 Million USD |
| Reuters | $705.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.